Prakashchandra Shetty

Prakashchandra Shetty

orcid

Research Focus & Metrics

Representative Publications

View All Publications
15 January 2021 in Scientifica
Verified
Journal Article
Open access
PDF file
AAAkheruz Zaman Ahmed
Akheruz Zaman Ahmed
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
PSPrakashchandra Shetty
Prakashchandra Shetty
MDMelanie Rose D’souza
Melanie Rose D’souza
Doxorubicin-induced cardiotoxicity is the leading cause of morbidity and mortality among cancer survivors. The present study was aimed to investigate the cardioprotective potential of methyl gallate; an active polyphenolic nutraceutical, against doxorubicin-induced cardiotoxicity in Wistar rats. Twenty-four female Wistar rats (150–200 g) were divided into four groups (n = 6) which consist of normal control (group I), doxorubicin control (group II), test-A (group III), and test-B (group IV). Group III and group IV animals were prophylactically treated with methyl gallate 150 mg/kg/day and 300 mg/kg/day orally, respectively, for seven days. Doxorubicin (25 mg/kg; single dose) was administered through an intraperitoneal route to group II, III, and IV animals on the seventh day to induce acute cardiotoxicity. On the 8th day, besides ECG analysis, serum CK, CK-MB, LDH, AST, MDA, and GSH were assayed. Following gross examination of isolated hearts, histopathological evaluation was performed by light microscopy. A significant ( < 0.05) cardiac injury, as well as oxidative stress, was observed in doxorubicin control rats in comparison to normal control rats. Methyl gallate at both the doses significantly ( < 0.05) reduced doxorubicin-induced ECG changes, dyslipidaemia, and elevation of CK, CK-MB, LDH, AST, MDA and increased GSH level. Methyl gallate reversed the doxorubicin-induced histopathological changes in the heart. The present study revealed that methyl gallate exerts cardioprotection against doxorubicin-induced cardiotoxicity in female Wistar rats by suppressing oxidative stress. Our study opens the perspective to clinical studies for consideration of methyl gallate as a potential chemoprotectant nutraceutical in the combination chemotherapy with doxorubicin to limit its cardiotoxicity.

19 March 2021 in Cardiovascular Toxicology
Verified
Journal Article
Open access
PDF file
AAAkheruz Zaman Ahmed
Akheruz Zaman Ahmed
KMKamalesh D. Mumbrekar
Kamalesh D. Mumbrekar
SSShakta Mani Satyam
Shakta Mani Satyam
PSPrakashchandra Shetty
Prakashchandra Shetty
MDMelanie Rose D’sOuza
Melanie Rose D’sOuza
VSVarun Kumar Singh
Varun Kumar Singh
Doxorubicin (DOX) is a potent anti-cancer antibiotic that was widely used for treatment of various cancers. It produces free radicals which result in extreme dose-limiting cardiotoxicity. This study investigated the cardioprotective potential of chia seed oil, an active polyphenolic nutraceutical against doxorubicin-induced cardiotoxicity in Wistar rats. Twenty-four female Wistar rats were divided into four groups (n = 6) which consist of normal control, DOX control, test-A and test-B group. Animals were prophylactically treated with two different doses of test drug, i.e. chia seed oil 2.5 ml/kg/day and 5 ml/kg/day in test-A and test-B groups orally for 7 days. Doxorubicin (25 mg/kg; single dose) was administered intraperitoneally to DOX control, Test-A and Test-B animals on the seventh day to induce cardiotoxicity. ECG analysis was done before and after treatment. Besides ECG, CK, CK-MB, LDH, AST, MDA and GSH were analyzed. DOX had significantly altered ECG, CK, CK-MB, LDH, AST, MDA and GSH. Pre-treatment with chia seed oil significantly alleviated DOX-induced ECG changes and also guarded against DOX-induced rise of serum CK, CK-MB and AST levels. Chia seed oil alleviated histopathological alteration in DOX-treated rats. It also significantly inhibited DOX-induced GSH depletion and elevation of MDA. The present study revealed that chia seed oil exerts cardioprotection against doxorubicin-induced cardiotoxicity in female Wistar rats. Our study opens the perspective to clinical studies to precisely consider chia seed oil as a potential chemoprotectant nutraceutical in the combination chemotherapy with doxorubicin to limit its cardiotoxicity.

25 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ARAbdul Rehman
Abdul Rehman
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
SPSainath P
Sainath P
RKRashmi Kumari
Rashmi Kumari
BABasma Ammar Alomar
Basma Ammar Alomar
Metformin, a long-established antidiabetic agent, is undergoing a renaissance as a prototype gerotherapeutic and immunometabolic oncology adjuvant. Mechanistic advances reveal that metformin modulates an integrated network of metabolic, immunological, microbiome-mediated, and epigenetic pathways that impact the hallmarks of aging and cancer biology. Clinical data now demonstrate its ability to reduce cancer incidence, enhance immunotherapy outcomes, delay multimorbidity, and reverse biological age markers. Landmark trials such as UKPDS, CAMERA, and the ongoing TAME study illustrate its broad clinical impact on metabolic health, cardiovascular risk, and age-related disease trajectories. In oncology, trials such as MA.32 and METTEN evaluate its influence on progression-free survival and tumor response, highlighting its evolving role in cancer therapy. This review critically synthesizes the molecular underpinnings of metformin’s polypharmacology, examines results from pivotal clinical trials, and compares its effectiveness with emerging gerotherapeutics and senolytics. We explore future directions, including optimized dosing, biomarker-driven personalization, rational combination therapies, and regulatory pathways, to expand indications for aging and oncology. Metformin stands poised to play a pivotal role in precision strategies that target the shared roots of aging and cancer, offering scalable global benefits across health systems.

1 May 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
MEMohamed El-Tanani
Mohamed El-Tanani
AAAkheruz Zaman Ahmed
Akheruz Zaman Ahmed
MRManfredi Rizzo
Manfredi Rizzo
DPDimitrios Patoulias
Dimitrios Patoulias
SPSainath Prabhakar
Sainath Prabhakar
Background: Nutraceuticals like methyl gallate and chia seed oil are gaining global attention for their therapeutic potential. This study investigates their effects on hepatocyte apoptosis and liver architecture in a doxorubicin-induced hepatotoxicity model, utilizing techniques such as TUNEL assay, immunohistochemistry (Bax & Bcl2), H&E staining, and scanning electron microscopy. Methodology: Thirty female Wistar rats were divided into five groups (n=6): Group I (Normal healthy control), Group II (Doxorubicin-intoxicated control), Group III (Doxorubicin-intoxicated + methyl gallate), Group IV (Doxorubicin-intoxicated + chia seed oil), and Group V (Doxorubicin-intoxicated + both). Liver function tests, histology, and cell apoptosis analysis were performed to assess the effects. Results: Doxorubicin-intoxicated rats (Group II) exhibited significantly elevated ALT, AST, and ALP levels (p < 0.001) and severe hepatic damage compared to controls. Group III and Group IV showed significant reductions in liver enzyme levels (p < 0.05 and p < 0.01, respectively), while Group V demonstrated the most significant decrease (p < 0.001). Immunohistochemistry revealed increased Bax and decreased Bcl2 expression in Group II (p < 0.001), which improved significantly with methyl gallate, chia seed oil, and their combination (p < 0.05 to p < 0.001). TUNEL assay showed reduced apoptotic index in treatment groups, with Group V showing the most significant reduction (p < 0.001). Scanning electron microscope (SEM) analysis confirmed restoration of hepatocyte architecture, especially in Group V. Conclusion: Methyl gallate and chia seed oil, individually and in combination, demonstrated significant hepatoprotective effects against doxorubicin-induced hepatotoxicity, with the combination showing the greatest efficacy. These nutraceuticals hold promise as adjunct therapies to reduce doxorubicin-induced liver injury.

16 February 2023 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
LBLAXMINARAYANA KURADY BAIRY
LAXMINARAYANA KURADY BAIRY
PSPrakashchandra Shetty
Prakashchandra Shetty
Introduction: Differences in pain thresholds may have implications in pain management, as they may account in part for the variability in analgesic requirements between individuals. We planned to investigate the influence of endogenous sex hormones on the analgesic modulation of tramadol in lean and high-fat diet-induced obese Wistar rats. Methods: The whole study was carried out on 48 adult Wistar rats (24 male: 12 obese and 12 lean and 24 female: 12 obese and 12 lean). Each male and female rat group was further subdivided into two groups (n = 6/group) and treated with normal saline/tramadol for 5 days. On the fifth day, 15 min after tramadol/normal saline treatment, animals were tested for pain perception toward noxious stimuli. Later, endogenous 17 beta-estradiol and free testosterone levels in serum were estimated through ELISA methods. Results: The present study revealed that female rats experienced more pain sensitivity to noxious stimuli compared to male rats. High-fat diet-induced obese rats experienced more pain sensations to noxious stimuli than lean rats. Obese male rats were found to have significantly low free testosterone and high 17 beta-estradiol levels compared to lean male rats. An increase in serum 17 beta-estradiol level led to increased pain sensation to noxious stimuli. While an increase in free testosterone level resulted in the lowering of pain sensation to noxious stimuli. Conclusion: The analgesic effect of tramadol was more pronounced in male rats compared to female rats. The analgesic effect of tramadol was more marked in lean rats compared to obese rats. Additional research to elucidate obesity-induced endocrine changes and the mechanisms driving sex hormones in pain perception is needed to foster future interventions to reduce disparities in pain.

1 January 2019 in Anatomy & Cell Biology
Verified
Journal Article
Open access
PDF file
PSPrakashchandra Shetty
Prakashchandra Shetty
SNSatheesha B Nayak
Satheesha B Nayak
Shetty P, et al. Anat Cell Biol. 2019 Aug;52:e12. https://doi.org/10.5115/acb.19.018